Preclinical development of novel small molecule malaria drugs that overcome drug

描述(申请人提供)：由于抗药性寄生虫的传播，疟疾造成的全球健康问题变得更加困难。我们已经开发出一种口服可用且价格低廉的新型药物，既可对抗氯喹耐药性疟疾，也可对抗氯喹敏感疟疾。该项目进行了一种候选药物的临床前开发，该候选药物是从这类创新的有效抗疟疾药物中挑选出来的，旨在克服耐药性。候选人将通过临床前测试的最终阶段晋级。因此，将在大鼠和猴子身上进行药代动力学、药效学、药理学和毒性评估。总体目标将是完成临床前研究，从而批准用于第一阶段人体临床试验的研究新药(IND)申请。

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical development of a drug candidate that has been selected from this innovative class of potent antimalarials designed to overcome drug resistance. The candidate will be advanced through the ultimate stages of preclinical testing. Thus, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys. The overall goal will be completion of preclinical studies leading to approval of an Investigative New Drug (IND) application for the drug to be used in a Phase 1 human clinical trial.